RYTM earnings analysis
What we found in RYTM's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Rhythm delivered a strong Q2 top-line result, with $71.3 million of IMCIVREE revenue up 19% sequentially and 47% year over year, led by a 38% sequential increase in U.S. revenue after the acquired-HO launch. Margins and EPS improved sequentially, but the company remains loss-making as SG&A expanded 47% year over year to support commercialization, while a $3.8 million France rebate charge reduced international sales. Liquidity of $330.9 million supports at least 24 months of planned operations, though management continues to expect additional financing needs as it funds global launches and pipeline trials.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue accelerated to $71.3M
- Q2 product revenue was $71.3 million, up 19% sequentially and 47% from $48.5 million in Q2 2025. Revenue exceeded the reported $67.2 million consensus estimate by 6.04%.
- U.S. acquired-HO launch drove growth
- U.S. revenue reached $51.0 million, up $14.1 million, or 38%, versus Q1, driven primarily by acquired hypothalamic obesity demand and continued BBS growth. More than 400 acquired-HO patient start forms had been received from approximately 300 prescribers as of June 30.
- Operating leverage improved sequentially
- Gross margin was 87.5% ($71.3 million revenue less $8.9 million cost of sales), down from 88.1% in Q1 but still high. Operating margin improved to negative 68.1% from negative 87.1% in Q1 and negative 93.4% in Q2 2025 as revenue outpaced expenses.
- EPS beat and sequential improvement
- Diluted EPS was negative $0.73, improving from negative $0.83 in Q1 and negative $0.75 in Q2 2025, and ahead of the negative $0.84 consensus estimate.
- Cash runway supports development plan
- Operating cash use improved to $53.3 million for the first six months of 2026 from $63.7 million a year earlier. Cash, cash equivalents and short-term investments were $330.9 million at June 30, which management says funds planned operations for at least 24 months.
- Clinical data support MC4R platform
- The acquired-HO pipeline and launch opportunity advanced: the Phase 3 TRANSCEND study showed an 18.4% placebo-adjusted BMI reduction, while preliminary RM-718 data showed an 11.6% mean BMI reduction at 16 weeks in 7 patients.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Commercial buildout keeps losses elevated
- Despite 47% revenue growth, net loss increased 6% year over year to $49.3 million. SG&A rose 47% to $67.4 million, including $18.7 million higher personnel costs, while R&D rose 3% to $43.4 million.
- France rebate charge pressured ex-U.S. sales
- Ex-U.S. revenue declined 13% sequentially to $20.3 million because of a $3.8 million retrospective rebate charge in France, of which $3.1 million related to revenue recorded before Q2. This illustrates reimbursement and rebate volatility in international markets.
- Receivables and inventory absorbed cash
- Working-capital growth consumed cash: accounts receivable increased $14.3 million and inventory increased $5.4 million in the first six months of 2026. Management also states it may need additional funding beyond its stated 24-month cash runway.
- Royalty financing and milestones weigh on cash
- The company has paid $51.5 million under its revenue-interest financing agreement as of June 30, 2026, and potential milestone payments of up to $18 million could become payable during the next 12 months. These obligations can constrain cash available for development and commercialization.
- Early RM-718 data have small-sample risk
- Management’s preliminary RM-718 data are based on only 11 enrolled acquired-HO patients, with 7 evaluable at 16 weeks; 2 participants discontinued because of adverse events. The filing cautions preliminary and interim data may change after full review and audit.
- New data-security compliance exposure
- A material regulatory-risk update notes the U.S. DOJ Data Security Program became effective April 8, 2025 and fully enforceable July 9, 2025. Noncompliance could result in significant civil or criminal penalties and may require changes to data transfers and vendors.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.73
- Gross margin
- 87.47%
- Operating margin
- -68.14%
- Segment
- U.S. product revenue: $51.0 million (72% of product revenue), up $14.1 million or 38% sequentially.
- Segment
- Ex-U.S. product revenue: $20.3 million (28% of product revenue), down $2.9 million or 13% sequentially; included a $3.8 million France retrospective-rebate charge.
What they said about what is next.
The 10-Q provides no quantitative revenue or EPS outlook. Management expects existing cash, cash equivalents and short-term investments of $330.9 million to fund planned operations for at least 24 months; it anticipates a Japan acquired-HO launch by year-end 2026, a pivotal bivamelagon Phase 3 initiation by year-end 2026, and European acquired-HO launches beginning in 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 5, 2026
- Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1 million, beating expectations of $56.2 million, while EPS of -$0.83 slightly missed estimates. The company anticipates $385 million to $415 million in operating…
- 10-K · February 26, 2026
- Rhythm is a commercial-stage biopharma focused on MC4R agonists led by IMCIVREE (setmelanotide). The company reported continued product revenue growth (Q4 2025 net product revenues $57,253,000) while remaining…
- 10-Q · August 5, 2025
- Rhythm Pharmaceuticals reported a significant revenue increase of 68% quarter-over-quarter, from $29 million in Q2 2024 to $49 million in Q2 2025. However, net loss widened compared to the previous year, reflecting…
- 10-K · February 28, 2025
- Rhythm reports a commercial-stage business centered on IMCIVREE (setmelanotide) with clear near-term clinical catalysts (Phase 3 topline for acquired hypothalamic obesity expected Q2 2025) and multi-quarter revenue…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RYTM makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever